Pemvidutide Side Effects: What Studies Report

What pemvidutide is, and what this page covers

Pemvidutide has been described in the peer-reviewed literature as a GLP-1/glucagon dual receptor agonist given by once-weekly subcutaneous injection and evaluated in metabolic dysfunction-associated steatotic liver disease (MASLD) in a randomised, double-blind, placebo-controlled study (Journal of Hepatology, 2025). A 2024 review of approved and emerging hormone-based anti-obesity medications grouped pemvidutide with other multi-receptor incretin agents still in clinical development rather than with approved products (Indian Journal of Endocrinology and Metabolism, 2024). It is an investigational compound and is not an approved medicine. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or treatment decision. Mechanism, receptor pharmacology and trial design are covered in PeptideU's pemvidutide course material; this page stays narrowly on what published studies reported about adverse events and tolerability.

Where the reported safety data come from

Safety statements about pemvidutide in the public literature rest on a small number of randomised trials in liver disease populations, plus reviews and meta-analyses that pooled or contextualised those trials. The table below lists the verified sources used on this page and the dose levels each described.

Gastrointestinal Adverse Events: What Studies Report

Across the randomised trials, gastrointestinal complaints dominated the adverse-event tables. In the randomised, double-blind, placebo-controlled MASLD study, researchers reported that adverse events were mostly gastrointestinal — nausea and vomiting being the events described most often — and were characterised as predominantly mild to moderate in severity (PMID 39002641). The 24-week randomised controlled trial in MASLD likewise reported gastrointestinal events as the most common tolerability finding at the 1.2 mg, 1.8 mg and 2.4 mg weekly dose levels (PMID 41113119).

The 24-week results of the IMPACT phase 2b study in metabolic dysfunction-associated steatohepatitis reported safety and tolerability alongside histological endpoints for weekly pemvidutide 1.2 mg and 1.8 mg compared with placebo, with gastrointestinal events again the most frequently recorded category (PMID 41237796). Reviews of incretin-based obesity pharmacotherapy have framed this pattern as typical of the class rather than unique to any single molecule, noting that gastrointestinal intolerance is the most common reason such agents are described as difficult to tolerate (PMID 39676791).

Readers comparing event rates across these papers should consult the original adverse-event tables directly, because the trials differed in population, duration, titration scheme and how investigators graded severity.

Dose Level and Discontinuation: What Studies Report

Dose level is the variable the published trials examined most systematically. The MASLD studies tested 1.2 mg, 1.8 mg and 2.4 mg weekly against placebo (PMID 39002641), and the 24-week MASLD trial repeated that dose range over a longer exposure period (PMID 41113119). The phase 2b MASH trial carried forward the two lower weekly dose levels, 1.2 mg and 1.8 mg, into a fibrosis-staged population (PMID 41237796). The narrowing of the dose range between programmes is itself a safety-relevant observation, and the trial reports are the correct place to read how investigators justified it.

Treatment discontinuation and withdrawal because of adverse events were prespecified safety outcomes in these randomised trials and were reported for each dose group against placebo (PMID 41237796). The GRADE-assessed meta-analysis of randomised trials in MASH also examined safety outcomes, including adverse-event-related withdrawals, when grading the certainty of the evidence base (PMID 41879841). Neither this page nor the underlying papers support any statement about how an individual would tolerate a given dose.

Pooled Safety Findings Across Trials: What Studies Report

Two 2026 quantitative syntheses are the closest thing the literature offers to an aggregate safety picture. The GRADE-assessed meta-analysis of randomised controlled trials evaluated both efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis and applied formal certainty ratings to each pooled outcome (PMID 41879841). A separate systematic review and meta-analysis assessed the efficacy and safety of dual and triple GLP-1-based polyagonists as a group in MASLD and steatohepatitis, placing pemvidutide's reported adverse-event profile beside those of other multi-receptor agents (PMID 42529769).

Both syntheses were constrained by the same limitation: a small number of randomised trials, short follow-up and heterogeneous populations. The certainty grades attached to pooled safety estimates in the GRADE analysis are therefore as informative as the point estimates themselves (PMID 41879841).

Liver and Metabolic Measures Tracked Alongside Adverse Events: What Studies Report

In the randomised MASLD studies, researchers tracked liver fat content and metabolic laboratory parameters as efficacy endpoints while simultaneously collecting safety data, so the published safety narrative cannot be read in isolation from those measures (PMID 39002641). The 24-week MASLD trial reported both efficacy and safety outcomes over the full treatment period (PMID 41113119), and the phase 2b MASH study paired histology-based endpoints with 24-week safety reporting (PMID 41237796). Reviews of glucagon receptor agonist combinations have noted that glucagon co-agonism introduces metabolic monitoring considerations that differ from single GLP-1 receptor agonism, which is why laboratory surveillance featured in these trial protocols (PMID 40734920).

Class-Level Context for Glucagon Co-Agonism: What Studies Report

A 2025 review of emerging concepts in obesity management examined glucagon receptor agonist combinations specifically and discussed how adding glucagon receptor activity to GLP-1 receptor agonism changes the expected efficacy and monitoring profile relative to GLP-1-only agents (PMID 40734920). The 2024 review of hormone-based anti-obesity medications similarly situated dual agonists within a development pipeline where tolerability, chiefly gastrointestinal, has been the recurring limiting factor across molecules (PMID 39676791). Class-level statements are context, not substitutes for compound-specific trial data, and the reviews present them as such.

Where published safety data are absent

Several gaps are best stated plainly as absence rather than inferred:

• Long-term exposure. The randomised evidence summarised above covered treatment periods in the range of the 24-week results reported for MASLD and MASH (PMID 41113119) (PMID 41237796). Multi-year safety data are not part of this published record.
• Cardiovascular outcome data. None of the verified papers reported a dedicated cardiovascular outcomes trial for pemvidutide.
• Special populations. The verified literature contains no pemvidutide safety data in pregnancy, lactation, paediatric populations or advanced renal or hepatic impairment.
• Non-liver indications. A 2026 systematic review of ClinicalTrials.gov catalogued registered GLP-1 receptor agonist studies in substance use disorders, showing that registry entries exist in this space while published safety results remain limited (PMID 41696398).
• Real-world use. Because pemvidutide is investigational, there is no post-marketing surveillance dataset comparable to those available for approved incretin agents (PMID 39676791).

How these safety reports are structured

Each randomised trial reported adverse events by treatment group, by severity grading and by whether investigators judged them treatment-emergent, and the meta-analyses pooled those group-level counts (PMID 41879841). Three features of that structure matter when the numbers are read:

1. Group-level, not individual-level. A reported frequency describes a randomised cohort, not a prediction for any person.
2. Placebo comparison is essential. Nausea and related symptoms occur in placebo arms too, which is why the trial reports present both columns (PMID 41237796).
3. Population specificity. The safety data came from MASLD and MASH cohorts (PMID 39002641), and extrapolation beyond those populations is not supported by the papers.

Key points from the published record

• Gastrointestinal adverse events, chiefly nausea and vomiting and described as mostly mild to moderate, were the most frequently reported findings in the randomised MASLD study (PMID 39002641).
• Weekly doses of 1.2 mg, 1.8 mg and 2.4 mg appeared in the MASLD trials (PMID 41113119), while the phase 2b MASH trial reported 24-week results for 1.2 mg and 1.8 mg weekly versus placebo (PMID 41237796).
• Two 2026 meta-analyses pooled safety with efficacy and highlighted the limited number and duration of available randomised trials (PMID 41879841) (PMID 42529769).
• Pemvidutide remains investigational, and reviews list it among emerging rather than approved agents (PMID 39676791).

This page reports what the cited studies stated and does not recommend, endorse or discourage any use of any compound. Anyone with clinical questions should raise them with a licensed physician.

References

• Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study (Journal of Hepatology, 2025)
• Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study (Lancet, 2025)
• Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial (JHEP Reports, 2025)
• Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials (Naunyn-Schmiedeberg's Archives of Pharmacology, 2026)
• Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis (Cureus, 2026)
• Review: Real-world evidence on the use of GLP1 receptor agonists: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations (Drugs in Context, 2025)
• Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article (Indian Journal of Endocrinology and Metabolism, 2024)
• Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov (Addictive Behaviors Reports, 2026)